Currently Viewing:
Newsroom
Currently Reading
What's the Magic Payment Mix for Medicare Primary Care Providers?
December 11, 2017 – Allison Inserro
Sanofi's Insulin Lispro Follow-On, Admelog, Wins FDA Approval
December 11, 2017 – Mary Caffrey
The Past, Present, and Future of HIV Funding
December 11, 2017 – Jaime Rosenberg
What We're Reading: Harsh Flu Season; Potential Hospital Giants Merger; ACA Sign-Up Deadline
December 11, 2017 – AJMC Staff
ICER Seeking Public Comment About Migraine, Plaque Psoriasis Treatments
December 11, 2017 – Allison Inserro
ADA 2018 Standards Address Drugs With CV Benefits, Hold Firm on Blood Pressure
December 10, 2017 – Mary Caffrey
Heavy Healthcare Use Precedes Start of Acthar Injection for Patients With Rare Infantile Spasms
December 09, 2017 – Mary Caffrey
UC San Diego Researchers Receive $600,000 Grant to Test PI3Ky Inhibitor
December 08, 2017 – Kelly Davio
5 Approvals and Updates From the FDA This Week
December 08, 2017 – Jaime Rosenberg

The Promise of Merck's Pembrolizumab in PD-L1-expressing NSCLC

Pembrolizumab was safe and effective in patients with locally advanced or metastatic non—small cell lung cancer that strongly expressed PD-L1, according to study results presented at the ASCO Annual Meeting.

Edward B. Garon, MD, assistant clinical professor and director of the thoracic oncology program at the David Geffen School of Medicine at the University of California, Los Angeles, and colleagues sought to evaluate pembrolizumab (Merck) — previously known as lambrolizumab and MK-3475 — among patients with previously treated advanced NSCLC.

“We presented the initial data from lung cancer patients at the World Conference on Lung Cancer in Sydney last fall,” Garon told HemOnc Today. “The question at that time was whether the impressive efficacy and tolerable safety profile could be confirmed in a larger population. We have now demonstrated similar results in over 200 additional patients.”

The analysis included 217 patients who were tested for PD-L1 expression using immunohistochemistry (IHC).

Read the report here: http://bit.ly/1kn49ov

Source: Healio


 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!